Nov. 01, 2025
CamGene Therapeutics Secures Oversubscribed Seed Round to Advance RNA-Based Hearing Loss Therapies
CAMBRIDGE, UNITED KINGDOM – CamGene Therapeutics, a biotechnology company developing first-in-class RNA-based therapies for hearing loss, has announced the successful closing of its oversubscribed seed funding round. The financing was led by the UK Innovation & Science Seed Fund (UKI2S), managed by Future Planet Capital, and joined by majority investor Eos Advisory, as well as Cambridge Enterprise Ventures, Hex Two, LongRiver












